NCT02086500

Brief Summary

The purpose of this study is to determine if 1 gram of prehospital tranexamic acid given during emergency medical transport to a level 1 trauma center in patients at risk of hemorrhage is associated with lower 30 day mortality.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
903

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Jul 2015

Typical duration for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 6, 2014

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 13, 2014

Completed
1.3 years until next milestone

Study Start

First participant enrolled

July 1, 2015

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2019

Completed
10 months until next milestone

Results Posted

Study results publicly available

September 10, 2020

Completed
Last Updated

September 10, 2020

Status Verified

September 1, 2020

Enrollment Period

4.3 years

First QC Date

March 6, 2014

Results QC Date

July 11, 2020

Last Update Submit

September 9, 2020

Conditions

Keywords

Tranexamic acidrandomizedhemorrhageblinded

Outcome Measures

Primary Outcomes (1)

  • 30 Day Mortality

    Because not all patients had available data regarding 30-day mortality (patients were discharged and there 30-day outcome was unable to be determined) there may be differences between the 30Day mortality relative to the other outcomes. There were 5 and 4 patients from each arm that did not have 30-day outcome and thus are different.

    30 Day

Secondary Outcomes (6)

  • 24 Hour Mortality

    24 Hours

  • Acute Lung Injury

    7 days

  • Multiple Organ Failure

    30 days

  • Nosocomial Infection

    30 days

  • 24 Hour Total Blood Transfusion

    24 hours

  • +1 more secondary outcomes

Study Arms (2)

Prehospital Tranexamic Acid

EXPERIMENTAL

1 gram of Tranexamic Acid will be given during emergency medical transport

Drug: Tranexamic Acid

Control

PLACEBO COMPARATOR

Identical volume of saline during emergency medical transport

Other: Saline control

Interventions

1 gram of prehospital Tranexamic Acid

Prehospital Tranexamic Acid

Saline Control

Control

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Blunt or penetrating injured patients at risk of bleeding being transported via air or ground medical services from the scene of injury or from referring hospital to a definitive trauma center that is participating in the trial AND
  • Within 2 hours of time of injury AND
  • Hypotension (Systolic Blood Pressure (SBP) \< 90mmHg)
  • At scene of injury or during air or ground medical transport
  • Documented at referring hospital prior to air or ground medical transport arrival
  • Tachycardia (heart rate \>110 beats per minute)
  • At scene of injury or during air or ground medical transport
  • Documented at referring hospital prior to air or ground medical transport arrival

You may not qualify if:

  • Age \> 90 or \< 18 years of age
  • Inability to obtain intravenous access or intraosseous
  • Documented (radiographic evidence) cervical cord injury with motor deficit
  • Known prisoner
  • Known pregnancy
  • Traumatic arrest with \> 5 minutes CPR without return of vital signs
  • Penetrating cranial injury
  • Traumatic brain injury with brain matter exposed
  • Isolated drowning or hanging victims
  • Wearing an opt out bracelet.
  • Isolated fall from standing
  • Patient or Family Objection at scene

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Pittsburgh

Pittsburgh, Pennsylvania, 15213, United States

Location

Related Publications (3)

  • Lorence JM, Donohue JK, Iyanna N, Guyette FX, Gimbel E, Brown JB, Daley BJ, Eastridge BJ, Miller RS, Nirula R, Harbrecht BG, Claridge JA, Phelan HA, Vercruysse G, O'Keeffe T, Joseph B, Neal MD, Sperry JL. Characterization of adverse events in injured patients at risk of hemorrhagic shock: a secondary analysis of three harmonized prehospital randomized clinical trials. Trauma Surg Acute Care Open. 2024 Jun 25;9(1):e001465. doi: 10.1136/tsaco-2024-001465. eCollection 2024.

  • Gruen DS, Brown JB, Guyette FX, Johansson PI, Stensballe J, Li SR, Leeper CM, Eastridge BJ, Nirula R, Vercruysse GA, O'Keeffe T, Joseph B, Neal MD, Sperry JL. Prehospital tranexamic acid is associated with a dose-dependent decrease in syndecan-1 after trauma: A secondary analysis of a prospective randomized trial. J Trauma Acute Care Surg. 2023 Nov 1;95(5):642-648. doi: 10.1097/TA.0000000000003955. Epub 2023 May 1.

  • Guyette FX, Brown JB, Zenati MS, Early-Young BJ, Adams PW, Eastridge BJ, Nirula R, Vercruysse GA, O'Keeffe T, Joseph B, Alarcon LH, Callaway CW, Zuckerbraun BS, Neal MD, Forsythe RM, Rosengart MR, Billiar TR, Yealy DM, Peitzman AB, Sperry JL; STAAMP Study Group. Tranexamic Acid During Prehospital Transport in Patients at Risk for Hemorrhage After Injury: A Double-blind, Placebo-Controlled, Randomized Clinical Trial. JAMA Surg. 2020 Oct 5;156(1):11-20. doi: 10.1001/jamasurg.2020.4350. Online ahead of print.

MeSH Terms

Conditions

Hemorrhage

Interventions

Tranexamic Acid

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Cyclohexanecarboxylic AcidsAcids, CarbocyclicCarboxylic AcidsOrganic Chemicals

Results Point of Contact

Title
Dr. Jason Sperry MD, MPH
Organization
University of Pittsburgh

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
MD, MPH

Study Record Dates

First Submitted

March 6, 2014

First Posted

March 13, 2014

Study Start

July 1, 2015

Primary Completion

November 1, 2019

Study Completion

November 1, 2019

Last Updated

September 10, 2020

Results First Posted

September 10, 2020

Record last verified: 2020-09

Locations